Health ❯ Healthcare ❯ Pharmaceuticals

Drug Approval

FDA FDA Approval FDA Regulations Alzheimer's Disease FDA Approvals Lecanemab Clinical Trials Cancer Treatment Generic Drugs Anvisa

3 ARTICLES

5d ago

Trodelvy Approved in U.S. and EU as First‑Line Option for Metastatic Triple‑Negative Breast Cancer

This shift toward antibody‑drug conjugates could change frontline care by giving patients longer tumor control as survival benefits and access questions remain

3 ARTICLES

last wk.

FDA Approves First Generic Single‑Dose Flu Drug

4 ARTICLES

last wk.

FDA Approves Third Over-the-Counter Naloxone Nasal Spray

4 ARTICLES

2w ago

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

16 ARTICLES

2w ago

MHRA Approves Wegovy Daily Pill for Weight Loss in UK

5 ARTICLES

2w ago

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

4 ARTICLES

2w ago

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

8 ARTICLES

last mo.

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

4 ARTICLES

last mo.

EMA Recommends Jascayd for Two Progressive Lung Fibrosis Conditions

7 ARTICLES

last mo.

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

3 ARTICLES

last mo.

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

3 ARTICLES

last mo.

FDA Approves Bizengri for NRG1 Fusion Cholangiocarcinoma Under Accelerated Pathway

6 ARTICLES

last mo.

Cellular Intelligence Takes Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy

4 ARTICLES

last mo.

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

Drug Approval

Trodelvy Approved in U.S. and EU as First‑Line Option for Metastatic Triple‑Negative Breast Cancer

FDA Approves First Generic Single‑Dose Flu Drug

FDA Approves Third Over-the-Counter Naloxone Nasal Spray

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

MHRA Approves Wegovy Daily Pill for Weight Loss in UK

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

FDA Orders New Kidney Warning for Orlistat Weight‑Loss Pills

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis

FDA Expands Afrezza Inhaled Insulin Approval to Children Ages 6 and Up

Never miss stories about

Drug Approval

FDA Approves Decnupaz for Rare Blood Cancer

Anvisa Registers Ozivy as Brazil’s First Synthetic Semaglutide Analogue

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

EMA Recommends Jascayd for Two Progressive Lung Fibrosis Conditions

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

FDA Approves Bizengri for NRG1 Fusion Cholangiocarcinoma Under Accelerated Pathway

Cellular Intelligence Takes Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

Never miss stories about

Drug Approval